Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2019, Vol. 10 Issue (5) : 977-991     DOI: 10.14336/AD.2018.0921
Orginal Article |
Calcitriol Analogues Decrease Lung Metastasis but Impair Bone Metabolism in Aged Ovariectomized Mice Bearing 4T1 Mammary Gland Tumours
Artur Anisiewicz1, Beata Filip-Psurska1, Agata Pawlik1, Anna Nasulewicz-Goldeman1, Tomasz Piasecki2, Konrad Kowalski3, Magdalena Maciejewska1, Joanna Jarosz1, Joanna Banach1, Diana Papiernik1, Andrzej Mazur4, Andrzej Kutner5, Jeanette A Maier6, Joanna Wietrzyk1,*
1Department of Experimental Oncology, Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.
2Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland.
3Masdiag Sp. z o.o., Żeromskiego 33, Warsaw, Poland.
4Université Clermont Auvergne, INRA, UNH, Unité de Nutrition Humaine, F-63000 Clermont-Ferrand, France.
5Pharmaceutical Research Institute, 01-793 Warsaw, Poland.
6Università di Milano, Dept. Biomedical and Clinical Sciences, 20157 Milano, Italy
Download: PDF(1691 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

Calcitriol and its analogues are considered drugs supporting the anticancer treatment of breast cancer and preventing the osteoporosis that results from the development of cancer or from chemotherapy or hormone therapy. Following the orthotopic implantation of 4T1 mammary carcinoma cells into aged ovariectomized (OVX) mice, we evaluated the effects of calcitriol and its two analogues, PRI-2191 and PRI-2205, on metastatic spread and bone homeostasis. Calcitriol and its analogues temporarily inhibited the formation of metastases in the lungs. Unexpectedly, only mice treated with calcitriol analogues showed a deterioration of bone-related parameters, such as bone column density, marrow column density and the CaPO4 coefficient. These findings correlated with an increased number of active osteoclasts differentiated from bone marrow-derived macrophages in mice treated with the analogues. Interestingly, in the tumours from mice treated with PRI-2191 and PRI-2205, the expression of Tnfsf11 (RANKL) was increased. On the other hand, osteopontin (OPN) levels in plasma and tumour tissue, as well as TRAC5b levels in tumours, were diminished by calcitriol and its analogues. Despite a similar action of both analogues towards bone metabolism, their impact on vitamin D metabolism differed. In particular, PRI-2191 and calcitriol, not PRI-2205 treatment significantly diminished the levels of both 25(OH)D3 and 24,25(OH)2D3. In conclusion, though there is evident antimetastatic activity in old OVX mice, signs of increased bone metabolism and deterioration of bone mineralization during therapy with calcitriol analogues were observed.

Keywords breast cancer      elderly      ovariectomized mice      metastasis      calcitriol      vitamin D analogues     
Corresponding Authors: Wietrzyk Joanna   
About author:

These authors equally contributed to this work.

Just Accepted Date: 28 September 2018   Issue Date: 27 September 2019
E-mail this article
E-mail Alert
Articles by authors
Anisiewicz Artur
Filip-Psurska Beata
Pawlik Agata
Nasulewicz-Goldeman Anna
Piasecki Tomasz
Kowalski Konrad
Maciejewska Magdalena
Jarosz Joanna
Banach Joanna
Papiernik Diana
Mazur Andrzej
Kutner Andrzej
Maier Jeanette A
Wietrzyk Joanna
Cite this article:   
Anisiewicz Artur,Filip-Psurska Beata,Pawlik Agata, et al. Calcitriol Analogues Decrease Lung Metastasis but Impair Bone Metabolism in Aged Ovariectomized Mice Bearing 4T1 Mammary Gland Tumours[J]. Aging and disease, 2019, 10(5): 977-991.
URL:     OR
Figure 1.  Time course of experiment.
Figure 2.  The effect of calcitriol and its analogues on tumour progression in aged OVX mice. (A) Kinetics of tumour growth. (B) Tumour volume measured on the 21st day of the experiment. (C) Body weight kinetics. (D) Tumour blood perfusion estimated by ultrasound imaging as time to peak values measured on day 24 after 4T1 mammary gland inoculation. (E) Representative images of tumour perfusion in sham operated mice and OVX mice treated with vehicle or OVX mice treated with calcitriol (i) before and (ii) after contrast agent injection. (F) The number of mice diagnosed with metastases; graphs represent the number of mice with macroscopic metastatic nodules on days 14 and 21 (grey) and the number of mice in the group (N, blue). On the next days of observation in all animals, metastatic nodules were detected. (G) The number of lung metastases counted in fixed lungs on days 21, 28 and 33. Mice were ovariectomized (OVX) or sham operated (Sham); after 4 weeks, they were inoculated orthotopically with 4T1 cells (day 0). From day 7 (7 days after tumour inoculation), vitamin D analogues or vehicle were administered subcutaneously (s.c.) thrice weekly. The single doses of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. The number of mice analysed was 4-7 per group. Control mice (receiving the vehicle) are described as follows: "sham" - sham operated, tumour bearing mice; "control" - OVX, tumour bearing mice. Data presentation: (A) and (C) mean with standard deviation (SD); (B), (D) and (G) data for individual animals with mean and (SD). Statistical analysis: Kruskal-Wallis multiple comparison test. *P<0.05.
Figure 3.  The influence of calcitriol and its analogues on bone mineralization in mice bearing 4T1 tumours (day 0 and day 28). (A-E) Analysis performed on aged OVX mice. (F-I) Analysis performed on young mice. (A) and (F) Bone column density (corrected X-ray extinction for the cylindrical bone). (B) and (G) Marrow column density (corrected X-ray extinction for the marrow). (C) and (H) Bone density. (D) and (I) CaPO4 coefficient. (E) Representative X-ray pictures of aged OVX mice. Bruker In-Vivo FX PRO imaging equipped with an X-ray unit was used. Mice were ovariectomized (OVX) or sham operated (Sham), and after 4 weeks, they were inoculated orthotopically with 4T1 cells (day 0). From day 7 (7 days after tumour inoculation), vitamin D analogues or vehicle were administered subcutaneously (s.c.) thrice weekly. The single doses of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Both femurs of 3-6 mice were used for analysis. Control mice (receiving the vehicle) are described as follows: "sham" - sham operated, tumour bearing mice; "control" - OVX, tumour bearing mice. Day 0 means mice not inoculated with cancer cells, sham-operated or OVX. Statistical analysis: Kruskal-Wallis multiple comparison test. *p<0.05 compared to control mice on the relevant day of treatment or as indicated.
Figure 4.  Ca2+ plasma concentration and vitamin D metabolites in the blood; plasma and tumour cytokine levels in aged OVX mice bearing 4T1 mammary gland tumours and treated with calcitriol and its analogues. (A) Plasma concentration of Ca2+. The amount of vitamin D metabolites in whole blood: (B) 25(OH)D3, (C) 24,25(OH)2D3, (D) 25(OH)D2. (E) Osteopontin (OPN) level in mouse plasma and (F) tumour tissue. Plasma concentration of (G) RANKL and (I) osteocalcin. Tumour tissue levels of (H) RANKL, (J) osteocalcin, (K) TRAC5b. Mice were ovariectomized (OVX) or sham operated (Sham); after 4 weeks, they were inoculated orthotopically with 4T1 cells (day 0). From day 7 (7 days after tumour inoculation), vitamin D analogues or vehicle were administered subcutaneously (s.c.) thrice weekly. The single doses of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Number of samples analysed per group: 3-7. Control mice (receiving the vehicle) are described as follows: "sham" - sham operated, tumour bearing mice; "control" - OVX, tumour bearing mice. Day 0 means mice not inoculated with cancer cells, sham-operated or OVX. Statistical analysis: Kruskal-Wallis multiple comparison test. *P<0.05 compared to control mice on the relevant day of treatment or as indicated.
Figure 5.  Ex vivo osteoclastogenesis of bone marrow macrophages in aged OVX mice bearing 4T1 mammary gland tumours and treated with calcitriol or its analogues. (A) Active osteoclasts. TRAP-positive cells characterized by acid phosphatase staining (dark purple colour visible in the cytoplasm of cells) and more than five nuclei. BMDMs derived from mice on day 28 of the experiment were cultured with M-CSF (20 ng/ml) and RANKL (20 ng/ml). Mice were ovariectomized (OVX) or sham operated (Sham); after 4 weeks, they were inoculated orthotopically with 4T1 cells (day 0). From day 7 (7 days after tumour inoculation), vitamin D analogues or vehicle were administered subcutaneously (s.c.) thrice weekly. The single doses of compounds were as follows: calcitriol, 0.5 µg/kg; PRI-2191, 1.0 µg/kg; and PRI-2205, 10.0 µg/kg. Data are presented as the mean and standard deviation (SD). The percentage of cells compared to control mice is presented. The number of samples analysed was 4 per group. "Control" means OVX, tumour bearing mice. Statistical analysis: Sidak’s multiple comparison test. *P<0.05 compared to control mice. (B) Representative microphotographs of TRAP-positive osteoclasts. Scale bar = 1 mm.
Figure 6.  Heat maps of tumour tissue real-time PCR screening performed using the Mouse T Helper Cell Differentiation RT2 Profiler Array. Real-time PCR screening was performed using tumour tissue harvested on day 21. Data are presented as the mean fold change. The fold change (RQ) of target genes was defined using the double delta Ct method in reference to the heat shock protein 90 alpha (cytosolic), class B member 1 (Hsp90ab1). The results were adjusted to the values obtained for the control group (OVX, tumour-bearing, vehicle treated). Data analysis was performed using Qiagen online software suitable for the purchased kits (Qiagen, Hilden, Germany). Each reaction contained 0.5 µg of cDNA (for each mouse in the group; 3 or 4 mice per group).
Figure 7.  The main differences in the response to treatment with calcitriol and its analogues PRI-2191 and PRI-2205 between aged OVX and young mice bearing 4T1 breast cancer. Selected results of the analyses performed are presented. Young 6- to 8-week-old mice and aged 60-week-old ovariectomized (OVX) mice received an orthotopic injection of 4T1 mouse mammary gland cancer cells. Calcitriol (0.5 µg/kg), PRI-2191 (1 µg/kg) and PRI-2205 (10 µg/kg) were injected subcutaneously starting from day 7 and continuing three times a week to the end of the experiment.
[1] Piano A, Titorenko VI (2015). The intricate interplay between mechanisms underlying aging and cancer. Aging Dis, 6: 56-75
[2] Meehan B, Dombrovsky A, Lau K, Lai T, Magnus N, Montermini L, et al. (2013). Impact of host ageing on the metastatic phenotype. Mech Ageing Dev, 134: 118-29
[3] Klement H, St Croix B, Milsom C, May L, Guo Q, Yu JL, et al. (2007). Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy. Am J Pathol, 171: 1342-51
[4] Meehan B, Garnier D, Dombrovsky A, Lau K, D’Asti E, Magnus N, et al. (2014). Ageing-related responses to antiangiogenic effects of sunitinib in atherosclerosis-prone mice. Mech. Ageing Dev, 140: 13-22
[5] Boucher BJ (2012). The problems of vitamin D insufficiency in older people. Aging Dis, 3: 313-29
[6] Houston DK, Tooze JA, Hausman DB, Johnson MA, Nicklas BJ, Miller ME, et al. (2011). Change in 25-hydroxyvitamin D and physical performance in older adults. J Gerontol A Biol Sci Med Sci, 66: 430-6
[7] Hossein-nezhad A, Holick MF (2013). Vitamin D for health: a global perspective. Mayo Clin Proc, 88: 720-55
[8] Feldman D, Krishnan A V, Swami S, Giovannucci E, Feldman BJ (2014). The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer, 14: 342-57
[9] Rizzoli R, Body JJ, Brandi ML, Cannata-Andia J, Chappard D, El Maghraoui A, et al. (2013). Cancer-associated bone disease. Osteoporos Int, 24: 2929-53
[10] Dutta U, Pant K (2008). Aromatase inhibitors: Past, present and future in breast cancer therapy. Med Oncol, 25: 113-24
[11] Brown SA, Guise TA (2009). Cancer treatment-related bone disease. Crit Rev Eukaryot Gene Expr, 19: 47-60
[12] Jacot W, Pouderoux S, Thezenas S, Chapelle A, Bleuse JP, Romieu G, et al. (2012). Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat, 134: 709-17
[13] Singer O, Cigler T, Moore AB, Levine AB, Do HT, Mandl LA (2014). Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms. Breast J, 20: 174-9
[14] Zinser GM, Welsh J (2004). Accelerated mammary gland development during pregnancy and delayed postlactational involution in vitamin D 3 receptor null mice. Mol Endocrinol, 18: 2208-23
[15] Welsh JE, Zinser LN, Mianecki-Morton L, Martin J, Waltz SE, James H, et al. (2011). Age-related changes in the epithelial and stromal compartments of the mammary gland in normocalcemic mice lacking the vitamin D3 receptor. PLoS One, 6: e16479
[16] Chen L, Yang R, Qiao W, Yuan X, Wang S, Goltzman D, et al. (2018). 1,25-Dihydroxy vitamin D prevents tumorigenesis by inhibiting oxidative stress and inducing tumor cellular senescence in mice. Int J Cancer, 143: 368-82
[17] Milczarek M, Chodyński M, Filip-Psurska B, Martowicz A, Krupa M, Krajewski K, et al. (2013). Synthesis and biological activity of diastereomeric and geometric analogs of calcipotriol, PRI-2202 and PRI-2205, against human HL-60 leukemia and MCF-7 breast cancer cells. Cancers (Basel), 5: 1355-78
[18] Koli K, Keski-Oja J (1995). 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res, 55: 1540-6
[19] Kanazawa T, Enami J, Kohmoto K (1999). Effects of 1α,25-dihydroxycholecalciferol and cortisol on the growth and differentiation of primary cultures of mouse mammary epithelial cells in collagen gel. Cell Biol Int, 23: 481-7
[20] Krishnan A V, Swami S, Feldman D (2013). Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: Importance of mammary CYP27B1 for treatment and prevention. J Steroid Biochem Mol Biol, 136: 289-95
[21] Swami S, Krishnan A, Wang J, Jensen K, Horst R, Albertelli M, et al. (2012). Dietary vitamin D3 and 1,25-dihydroxyvitamin D3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer. Endocrinology, 153: 2576-87
[22] Jeong Y, Swami S, Krishnan A V, Williams JD, Martin S, Horst RL, et al. (2015). Inhibition of mouse breast tumor-initiating cells by calcitriol and dietary vitamin D. Mol. Cancer Ther., 14: 1951-61
[23] Wietrzyk J, Nevozhay D, Milczarek M, Filip B, Kutner A (2008). Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol, 62: 787-97
[24] Wietrzyk J, Pełczyńska M, Madej J, Dzimira S, Kuśnierczyk H, Kutner A, et al. (2004). Toxicity and antineoplastic effect of (24R)-1,24-dihydroxyvitamin D 3 (PRI-2191). Steroids, 69: 629-35
[25] Rossdeutscher L, Li J, Luco A-L, Fadhil I, Ochietti B, Camirand A, et al. (2015). Chemoprevention activity of 25-hydroxyvitamin D in the MMTV-PyMT mouse model of breast cancer. Cancer Prev Res (Phila), 8: 120-8
[26] Ooi LL, Zhou H, Kalak R, Zheng Y, Conigrave AD, Seibel MJ, et al. (2010). Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Res, 70: 1835-44
[27] Anisiewicz A, Pawlik A, Filip-Psurska B, Turlej E, Dzimira S, Milczarek M, et al. (2018). Unfavorable effect of calcitriol and its low-calcemic analogs on metastasis of 4T1 mouse mammary gland cancer. Int J Oncol, 52: 103-26
[28] Pawlik A, Anisiewicz A, Filip-Psurska B, Nowak M, Turlej E, Trynda J, et al. (2018). Calcitriol and its analogs establish the immunosuppressive microenvironment that drives metastasis in 4T1 mouse mammary gland cancer. Int J Mol Sci, 19: 2116
[29] Cao Y, Du Y, Liu F, Feng Y, Cheng S, Guan S, et al. (2018). Vitamin D aggravates breast cancer by inducing immunosuppression in the tumor bearing mouse. Immunotherapy, 10: 555-66
[30] Lappe J, Watson P, Travers-Gustafson D, Recker R, Garland C, Gorham E, et al. (2017). Effect of vitamin d and calcium supplementation on cancer incidence in older women. JAMA, 317: 1234
[31] Duffy MJ, Murray A, Synnott NC, O’Donovan N, Crown J (2017). Vitamin D analogues: Potential use in cancer treatment. Crit Rev Oncol Hematol, 112: 190-7
[32] Gulliford T, English J, Colston KW, Menday P, Moller S, Coombes RC (1998). A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer. Br J Cancer, 78: 6-13
[33] Medioni J, Deplanque G, Ferrero J-M, Maurina T, Rodier J-MP, Raymond E, et al. (2014). Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clin Cancer Res, 20: 4471-7
[34] Fu J, Wu L, Fu W, Tan Y, Xu T, Hong Z, et al. (2018). How young is too young in breast cancer?—Young breast cancer is not a unique biological subtype. Clin Breast Cancer, 18: 63-70
[35] LaPorta E, Welsh J (2014). Modeling vitamin D actions in triple negative/basal-like breast cancer. J Steroid Biochem Mol Biol, 144 Pt A: 65-73
[36] Brant J (2012). Vitamin D in the prevention of aromatase inhibitor-induced musculoskeletal symptoms: is it ready for practice? J Adv Pract Oncol, 3: 245-8
[37] Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, et al. (2017). Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol, 7: 1-12
[38] Handforth C, D’Oronzo S, Coleman R, Brown J (2018). Cancer treatment and bone health. Calcif Tissue Int, 102: 251-64
[39] Milczarek M, Psurski M, Kutner A, Wietrzyk J (2013). Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer, 13: 294
[40] Vizard DL, Wood DO, Papineni RVL, Feke GD, Orton SP, McLaughlin WE (2010). Analytical radiography for planar radiographic images implemented with a multi-modal system. Comput Methods Programs Biomed, 99: 88-97
[41] Vijayan V, Khandelwal M, Manglani K, Singh RR, Gupta S, Surolia A (2013). Homocysteine alters the osteoprotegerin/RANKL system in the osteoblast to promote bone loss: Pivotal role of the redox regulator forkhead O1. Free Radic Biol Med, 61: 72-84
[42] Ogawa S, Ooki S, Morohashi M, Yamagata K, Higashi T (2013). A novel Cookson-type reagent for enhancing sensitivity and specificity in assessment of infant vitamin D status using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom, 27: 2453-60
[43] Milczarek M, Rosinska S, Psurski M, Maciejewska M, Kutner A, Wietrzyk J (2013). Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res, 33: 433-44
[44] Maj E, Filip-Psurska B, Milczarek M, Psurski M, Kutner A, Wietrzyk J (2018). Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. Int J Oncol, 52: 337-66
[45] Maj E, Filip-Psurska B, Świtalska M, Kutner A, Wietrzyk J (2015). Vitamin D analogs potentiate the antitumor effect of imatinib mesylate in a human A549 lung tumor model. Int J Mol Sci, 16: 27191-207
[46] Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, et al. (2014). Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. Oncogene, 33: 2053-64
[47] Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, et al. (2005). Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther, 4: 740-6
[48] Sharon Y, Raz Y, Cohen N, Ben-Shmuel A, Schwartz H, Geiger T, et al. (2015). Tumor-derived osteopontin reprograms normal mammary fibroblasts to promote inflammation and tumor growth in breast cancer. Cancer Res, 75: 963-73
[49] Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, Ratti C, et al. (2014). Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res, 74: 4706-19
[50] Chang PL, Prince CW (1991). 1α,25-Dihydroxyvitamin D3 stimulates synthesis and secretion of nonphosphorylated osteopontin (Secreted Phosphoprotein 1) in mouse JB6 epidermal cells. Cancer Res, 51: 2144-50
[51] Chang PL, Ridall AL, Prince CW (1994). Calcitriol regulation of osteopontin expression in mouse epidermal cells. Endocrinology, 135: 863-9
[52] Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, et al. (2012). Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int, 82: 1261-70
[53] Guo B, Tumang JR, Rothstein TL (2009). B cell receptor crosstalk: B cells express osteopontin through the combined action of the alternate and classical BCR signaling pathways. Mol Immunol, 46: 587-91
[54] Drozdenko G, Scheel T, Heine G, Baumgrass R, Worm M (2014). Impaired T cell activation and cytokine production by calcitriol-primed human B cells. Clin Exp Immunol, 178: 364-72
[55] He X-J, Ding Y, Xiang W, Dang X-Q (2016). Roles of 1,25(OH)2D3 and Vitamin D receptor in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus by regulating the activation of CD4+ T cells and the PKCδ/ERK signaling pathway. Cell Physiol Biochem, 40: 743-56
[56] Verdeil G, Chaix J, Schmitt-Verhulst AM, Auphan-Anezin N (2006). Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation. Eur J Immunol, 36: 3090-100
[57] Bacon CM, Petricoin EF, Ortaldo JR, Rees RC, Larner AC, Johnston JA, et al. (1995). Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in human lymphocytes. Proc Natl Acad Sci USA, 92: 7307-11
[58] Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M (2017). The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal, 15: 23
[59] Oh Y, Oh I, Morimoto J, Uede T, Morimoto A (2014). Osteopontin has a crucial role in osteoclast-like multinucleated giant cell formation. J Cell Biochem, 115: 585-95
[60] Cong L, Zhang C, Tu G (2015). Osteoblastic NF-κB pathway is involved in 1α, 25(OH)2D3-induced osteoclast-like cells formation in vitro. Int J Clin Exp Pathol, 8: 5988-96
[61] Nakamichi Y, Udagawa N, Suda T, Takahashi N (2018). Mechanisms involved in bone resorption regulated by vitamin D. J Steroid Biochem Mol Biol, 177: 70-6
[62] Takahashi N, Udagawa N, Suda T (2014). Vitamin D endocrine system and osteoclasts. Bonekey Rep, 3: 495
[63] Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y, et al. (2002). Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res, 17: 622-9
[64] Takahashi N (2013). Mechanism of inhibitory action of Eldecalcitol, an active vitamin D analog, on bone resorption in vivo. J Steroid Biochem Mol Biol, 136: 171-4
[65] Starczak Y, Reinke DC, Barratt KR, Ryan JW, Russell PK, Clarke M V, et al. (2018). Absence of vitamin D receptor in mature osteoclasts results in altered osteoclastic activity and bone loss. J Steroid Biochem Mol Biol, 177: 77-82
[66] Milczarek M, Filip-Psurska B, Swietnicki W, Kutner A, Wietrzyk J (2014). Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep, 32: 491-504
[67] Matsunaga T, Yamamoto M, Mimura H, Ohta T, Kiyoki M, Ohba T, et al. (1990). 1,24(R)-dihydroxyvitamin D3, a novel active form of vitamin D3 with high activity for inducing epidermal differentiation but decreased hypercalcemic activity. J Dermatol, 17: 135-42
[68] Wietrzyk J, Chodyński M, Fitak H, Wojdat E, Kutner A, Opolski A (2007). Antitumor properties of diastereomeric and geometric analogs of vitamin D3. Anticancer Drugs, 18: 447-57
[69] Astecker N, Bobrovnikova EA, Omdahl JL, Gennaro L, Vouros P, Schuster I, et al. (2004). C-25 hydroxylation of 1α,24(R)-dihydroxyvitamin D3 is catalyzed by 25-hydroxyvitamin D3-24-hydroxylase (CYP24A1): metabolism studies with human keratinocytes and rat recombinant CYP24A1. Arch Biochem Biophys, 431: 261-70
[70] Moreau A, Maurel P, Vilarem M-J, Pascussi J-M (2007). Constitutive androstane receptor-vitamin D receptor crosstalk: consequence on CYP24 gene expression. Biochem Biophys Res Commun, 360: 76-82
[71] Masuda S, Strugnell S, Calverley MJ, Makin HL, Kremer R, Jones G (1994). In vitro metabolism of the anti-psoriatic vitamin D analog, calcipotriol, in two cultured human keratinocyte models. J Biol Chem, 269: 4794-803
[72] Bouillon R, Allewaert K, Xiang DZ, Tan BK, van Baelen H (2009). Vitamin D analogs with low affinity for the vitamin D binding protein: Enhanced in vitro and decreased in vivo activity. J Bone Miner Res, 6: 1051-7
[1] Tatiana Rafaela Lemos Lima, Vívian Pinto Almeida, Arthur Sá Ferreira, Fernando Silva Guimarães, Agnaldo José Lopes. Handgrip Strength and Pulmonary Disease in the Elderly: What is the Link?[J]. Aging and disease, 2019, 10(5): 1109-1129.
[2] Raquel Maeso-Díaz, Martí Ortega-Ribera, Erica Lafoz, Juan José Lozano, Anna Baiges, Rubén Francés, Agustín Albillos, Carmen Peralta, Juan Carlos García-Pagán, Jaime Bosch, Victoria C Cogger, Jordi Gracia-Sancho. Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease[J]. Aging and disease, 2019, 10(4): 684-698.
[3] Yaiza Potes, Zulema Pérez-Martinez, Juan C. Bermejo-Millo, Adrian Rubio-Gonzalez, María Fernandez-Fernández, Manuel Bermudez, Jose M. Arche, Juan J. Solano, Jose A. Boga, Mamen Oliván, Beatriz Caballero, Ignacio Vega-Naredo, Ana Coto-Montes. Overweight in the Elderly Induces a Switch in Energy Metabolism that Undermines Muscle Integrity[J]. Aging and disease, 2019, 10(2): 217-230.
[4] Binquan You, Bingbing Zhu, Xi Su, Feng Liu, Bingyin Wang. Gender Differences among Elderly Patients with Primary Percutaneous Coronary Intervention[J]. Aging and disease, 2018, 9(5): 852-860.
[5] da Rocha Erica Pires, Yokota Lais Gabriela, Sampaio Beatriz Motta, Cardoso Eid Karina Zanchetta, Dias Dayana Bitencourt, de Freitas Fernanda Moreira, Balbi Andre Luis, Ponce Daniela. Urinary Neutrophil Gelatinase-Associated Lipocalin Is Excellent Predictor of Acute Kidney Injury in Septic Elderly Patients[J]. Aging and disease, 2018, 9(2): 182-191.
[6] Wongrakpanich Supakanya, Wongrakpanich Amaraporn, Melhado Katie, Rangaswami Janani. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly[J]. Aging and disease, 2018, 9(1): 143-150.
[7] Wongrakpanich Supakanya, Kallis Christos, Prasad Prithiv, Rangaswami Janani, Rosenzweig Andrew. The Study of Rhabdomyolysis in the Elderly: An Epidemiological Study and Single Center Experience[J]. Aging and disease, 2018, 9(1): 1-7.
[8] Tortorella Lucia, Vizzielli Giuseppe, Fusco Domenico, Cho William C., Bernabei Roberto, Scambia Giovanni, Colloca Giuseppe. Ovarian Cancer Management in the Oldest Old: Improving Outcomes and Tailoring Treatments[J]. Aging and disease, 2017, 8(5): 677-684.
[9] Garcovich Simone, Colloca Giuseppe, Sollena Pietro, Andrea Bellieni, Balducci Lodovico, Cho William C., Bernabei Roberto, Peris Ketty. Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology[J]. Aging and disease, 2017, 8(5): 643-661.
[10] Chojin Yasuo, Kato Tatsuji, Rikihisa Mariko, Omori Masami, Noguchi Shingo, Akata Kentaro, Ogoshi Takaaki, Yatera Kazuhiro, Mukae Hiroshi. Evaluation of the Mann Assessment of Swallowing Ability in Elderly Patients with Pneumonia[J]. Aging and disease, 2017, 8(4): 420-433.
[11] De Martinis Massimo, Sirufo Maria Maddalena, Ginaldi Lia. Allergy and Aging: An Old/New Emerging Health Issue[J]. Aging and disease, 2017, 8(2): 162-175.
[12] Lee Su Jin, Kim Kyoung Min, Lee Eun Young, Song Mi Kyung, Kang Dae Ryong, Kim Hyeon Chang, Youm Yoosik, Yun Young Mi, Park Hyun-Young, Kim Chang Oh, Rhee Yumie. Low Normal TSH levels are Associated with Impaired BMD and Hip Geometry in the Elderly[J]. Aging and disease, 2016, 7(6): 734-743.
[13] Vancea Mihaela, Solé-Casals Jordi. Population Aging in the European Information Societies: Towards a Comprehensive Research Agenda in eHealth Innovations for Elderly[J]. Aging and disease, 2016, 7(4): 526-539.
[14] Figueiredo Daniela, Teixeira Laetitia, Poveda Veronica, Paúl Constança, Santos-Silva Alice, Costa Elísio. Predictors of Difficulty in Medication Intake in Europe: a Cross-country Analysis Based on SHARE[J]. Aging and disease, 2016, 7(3): 246-253.
[15] Xu Limin, Li Liqin, Li Jing, Li Hongwei, Shen Qibin, Ping Jinliang, Ma Zhihong, Zhong Jing, Dai Licheng. Overexpression of miR-1260b in Non-small Cell Lung Cancer is Associated with Lymph Node Metastasis[J]. Aging and disease, 2015, 6(6): 478-485.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd